Replies to post #726 on Oxford BioMedica PLC (OXBDF)

[georgejjl]

Marcus, Thank you!!!

On to the second deal with Axovant around our Parkinsons' drug OXB-102, now known as AXO-Lenti-PD. It's a worldwide licensing agreement here. Headline value of the deal was $842.5 million. The $30 million upfront here, $55 million was specified development milestones, and a further $757.5 million was specified regulatory and sales milestones. So on the drug here, the royalties we get are higher than we'd normally get in a partnership deal. We get tiered 7% to 10% on sales.

In March 2019, Axovant reported their data from the first cohort of the Phase 1/2 trial and are now planning to move into the second cohort of treatment in the second quarter. Very exciting in this, we're so excited where it can go.

Products in Parkinson's in 2016 sold $3.1 billion, set to rise on our forecast to about $8.8 billion by 2026. It's a huge market we are involved.

https://seekingalpha.com/article/4248943-oxford-biomedicas-oxbdf-ceo-john-dawson-q4-2018-results-earnings-call-transcript?part=single

Good luck and GOD bless,